To be eligible for the trial, patients had to have untreated locally advanced or metastatic NSCLC, ECOG performance status ...

The following is a summary of "Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma ...

A new deep learning model predicts which NSCLC patients will respond to immunotherapy, outperforming some traditional ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...

is currently used as a biomarker to determine the efficacy of PD-1 or PD-L1 targeted treatment in patients with NSCLC. However, due to heterogeneity of tPD-L1 expression and insufficient ...

The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more ...

Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...

in non-small cell lung cancer, which applies to England and Wales, NICE said the drug could be recommended for patients who express high levels of PD-L1, but want BMS to provide more data on these ...

Risk - EGFR-mutant NSCLC is a very unusual next shot on goal for cosibelimab With the lone exception of the IMpower150 regimen that incorporated targeted therapy, chemotherapy, and PD-L1 treatment ...

As it relates to Summits' running of the HARMONi-7 study, using ivonescimab as a monotherapy to target first-line metastatic NSCLC patients with high PD-L1 expression, Akeso with HARMONi-2 has ...

When used in conjunction with the PD-L1 IHC 28-8 pharmDx as a companion test, in the European Union: (a) resectable NSCLC patients with PD-L1 expression ≥1% and at high risk of recurrence may be ...

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications Agilent Technologies Inc. (NYSE: A) today ...